Dover Weakness Seen as Overdone and 4 Stock Analyses Attracting Attention

Gilead Sciences Inc. (NASDAQ:GILD): Current Price: $79.02

According to RBC Capital expectations, investors over the next 12-20 months may start giving Gilead credit for the development of a new HIV treatment that will be able to replace its current Viread treatment which is going generic in 2019. The firm believes that the stock may move towards or over $100 due to this factor, and it keeps its Outperform rating on the stock.

Capture

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Swift Transportation Company (NYSE:SWFT): Current Price: $13.49

RBC Capital decided to raise its target on Swift following the company’s reports of higher Q4 EPS than previously predicted. The firm keeps its Outperform rating on the stock.

Capture

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Dover Corp. (NYSE:DOV): Current Price: $67.21

According to Barclays, Dover weakness is a result of increased focus on its handset business, which is overdone. The analyst stated that Sound Solutions performance has shown improvement, and the company has significant market share with the majority of the major handset providers besides Apple. The firm predicts that the potential sale of non-core assets, share repurchases, and additional bolt-on acquisitions will act as near-term catalysts. The firm gives the stock an Overweight rating and a $75 price target.

Capture

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

ViroPharma Inc. (NASDAQ:VPHM): Current Price: $27.20

After the firm met with ViroPharma investors, Oppenheimer thinks that investors are concerned in regards to possible competition for the company in the prophylactic space. However, the firm is convinced that this concern is overblown, considering what it understands as under-appreciated hurdles for U.S. approval of competitive products. The firm keeps its Outperform rating on the stock.

Capture

Electronics for Imaging, Inc. (NASDAQ:EFII): Current Price: $23.00

Brean Capital decided to increase its price target on Electronics for Imaging as a result of solid Q4 results. The firm notes the company’s strong secular story and notes that the shares tend to trade up after strong quarters but is then followed by a pullback. Brean states that it would use any pullbacks as a buying opportunity. Shares have a Buy rating.

Capture

Investing Insights: Is McDonald’s Stock a Buy Now?